Adial Historical Financial Ratios

ADIL Stock

USD 0.99 0.01 0.90%

Adial Pharmaceuticals is presently reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.68 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Adial Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

About Adial Financial Ratios Analysis

Adial PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Adial Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Adial financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Adial Pharmaceuticals history.

Adial Pharmaceuticals Financial Ratios Chart

At this time, Adial Pharmaceuticals' EV To Operating Cash Flow is quite stable compared to the past year. Net Debt To EBITDA is expected to rise to 0.42 this year, although the value of Operating Cash Flow Per Share will most likely fall to (5.02).

Average Payables Payables Turnover Capex To Revenue Cash Per Share Days Payables Outstanding Roe

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Adial Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' EV To Operating Cash Flow is quite stable compared to the past year. Net Debt To EBITDA is expected to rise to 0.42 this year, although the value of Operating Cash Flow Per Share will most likely fall to (5.02).

Adial Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A
Ptb Ratio		-0.14	0.24	0.24	-0.07	-0.21	1.0	0.3	-0.51	0.17	-0.13	-0.2	-0.07	-0.45	-0.16	-0.07	-0.21	-0.16	-0.89	-0.06	-0.01	0.13	-0.06	0.25	-0.16	0.28
Book Value Per Share	-0.14		-0.02	-0.74	-0.02	-0.05	-0.14	-0.7	0.2	-0.87	-0.07	0.97	0.58	0.49	-0.04	0.58	0.16	-0.23	0.01	0.59	0.57	0.39	0.59	-0.1	-0.52	0.74
Free Cash Flow Yield	0.24	-0.02		0.12	0.15	-0.98	0.24	0.47	-0.18	-0.11	-0.27	0.08	-0.65	-0.56	-0.78	-0.65	0.0	-0.55	-0.1	-0.65	-0.61	-0.22	-0.64	1.0	0.12	-0.29
Operating Cash Flow Per Share	0.24	-0.74	0.12		-0.48	-0.02	0.24	0.9	-0.13	0.74	-0.39	-0.84	-0.77	-0.72	0.12	-0.77	-0.37	-0.11	0.06	-0.77	-0.74	-0.27	-0.77	0.17	0.16	-0.61
Average Payables	-0.07	-0.02	0.15	-0.48		-0.22	-0.07	-0.39	-0.23	-0.26	0.38	0.11	0.26	0.24	-0.19	0.26	0.36	-0.05	-0.23	0.25	0.24	0.07	0.25	0.13	0.08	0.0
Capex To Depreciation	-0.21	-0.05	-0.98	-0.02	-0.22		-0.21	-0.35	0.15	0.16	0.32	-0.16	0.56	0.48	0.72	0.56	-0.1	0.52	0.09	0.56	0.52	0.19	0.56	-0.97	-0.04	0.21
Pb Ratio	1.0	-0.14	0.24	0.24	-0.07	-0.21		0.3	-0.51	0.17	-0.13	-0.2	-0.07	-0.45	-0.16	-0.07	-0.21	-0.16	-0.89	-0.06	-0.01	0.13	-0.06	0.25	-0.16	0.28
Free Cash Flow Per Share	0.3	-0.7	0.47	0.9	-0.39	-0.35	0.3		-0.23	0.62	-0.29	-0.73	-0.92	-0.85	-0.3	-0.92	-0.36	-0.23	-0.02	-0.93	-0.89	-0.33	-0.93	0.52	0.3	-0.67
Roic	-0.51	0.2	-0.18	-0.13	-0.23	0.15	-0.51	-0.23		-0.22	-0.32	0.27	0.19	0.63	0.24	0.19	0.53	-0.17	0.69	0.18	0.28	-0.68	0.18	-0.21	0.33	-0.26
Net Income Per Share	0.17	-0.87	-0.11	0.74	-0.26	0.16	0.17	0.62	-0.22		-0.12	-0.91	-0.49	-0.52	0.18	-0.49	-0.17	0.43	0.03	-0.5	-0.52	-0.16	-0.5	-0.02	0.21	-0.46
Payables Turnover	-0.13	-0.07	-0.27	-0.39	0.38	0.32	-0.13	-0.29	-0.32	-0.12		0.03	0.33	0.28	-0.18	0.33	-0.34	0.33	-0.25	0.32	0.29	0.14	0.32	-0.26	0.44	0.04
Cash Per Share	-0.2	0.97	0.08	-0.84	0.11	-0.16	-0.2	-0.73	0.27	-0.91	0.03		0.57	0.56	-0.16	0.57	0.24	-0.22	0.05	0.58	0.57	0.24	0.58	0.01	-0.33	0.63
Pocfratio	-0.07	0.58	-0.65	-0.77	0.26	0.56	-0.07	-0.92	0.19	-0.49	0.33	0.57		0.84	0.42	1.0	0.3	0.3	-0.19	1.0	0.99	0.3	1.0	-0.69	-0.26	0.71
Interest Coverage	-0.45	0.49	-0.56	-0.72	0.24	0.48	-0.45	-0.85	0.63	-0.52	0.28	0.56	0.84		0.36	0.84	0.47	0.16	0.26	0.83	0.86	-0.15	0.83	-0.6	0.11	0.3
Capex To Operating Cash Flow	-0.16	-0.04	-0.78	0.12	-0.19	0.72	-0.16	-0.3	0.24	0.18	-0.18	-0.16	0.42	0.36		0.42	0.02	0.44	0.17	0.42	0.39	0.15	0.42	-0.79	-0.32	0.2
Pfcf Ratio	-0.07	0.58	-0.65	-0.77	0.26	0.56	-0.07	-0.92	0.19	-0.49	0.33	0.57	1.0	0.84	0.42		0.3	0.3	-0.19	1.0	0.99	0.3	1.0	-0.69	-0.26	0.71
Days Payables Outstanding	-0.21	0.16	0.0	-0.37	0.36	-0.1	-0.21	-0.36	0.53	-0.17	-0.34	0.24	0.3	0.47	0.02	0.3		0.03	0.29	0.29	0.33	-0.31	0.29	-0.01	-0.02	-0.01
Income Quality	-0.16	-0.23	-0.55	-0.11	-0.05	0.52	-0.16	-0.23	-0.17	0.43	0.33	-0.22	0.3	0.16	0.44	0.3	0.03		0.04	0.3	0.21	0.31	0.3	-0.5	-0.07	0.19
Roe	-0.89	0.01	-0.1	0.06	-0.23	0.09	-0.89	-0.02	0.69	0.03	-0.25	0.05	-0.19	0.26	0.17	-0.19	0.29	0.04		-0.2	-0.21	-0.36	-0.2	-0.11	0.18	-0.45
Ev To Operating Cash Flow	-0.06	0.59	-0.65	-0.77	0.25	0.56	-0.06	-0.93	0.18	-0.5	0.32	0.58	1.0	0.83	0.42	1.0	0.29	0.3	-0.2		0.98	0.32	1.0	-0.68	-0.27	0.72
Pe Ratio	-0.01	0.57	-0.61	-0.74	0.24	0.52	-0.01	-0.89	0.28	-0.52	0.29	0.57	0.99	0.86	0.39	0.99	0.33	0.21	-0.21	0.98		0.17	0.98	-0.65	-0.17	0.65
Return On Tangible Assets	0.13	0.39	-0.22	-0.27	0.07	0.19	0.13	-0.33	-0.68	-0.16	0.14	0.24	0.3	-0.15	0.15	0.3	-0.31	0.31	-0.36	0.32	0.17		0.32	-0.23	-0.81	0.74
Ev To Free Cash Flow	-0.06	0.59	-0.64	-0.77	0.25	0.56	-0.06	-0.93	0.18	-0.5	0.32	0.58	1.0	0.83	0.42	1.0	0.29	0.3	-0.2	1.0	0.98	0.32		-0.68	-0.27	0.72
Earnings Yield	0.25	-0.1	1.0	0.17	0.13	-0.97	0.25	0.52	-0.21	-0.02	-0.26	0.01	-0.69	-0.6	-0.79	-0.69	-0.01	-0.5	-0.11	-0.68	-0.65	-0.23	-0.68		0.15	-0.32
Intangibles To Total Assets	-0.16	-0.52	0.12	0.16	0.08	-0.04	-0.16	0.3	0.33	0.21	0.44	-0.33	-0.26	0.11	-0.32	-0.26	-0.02	-0.07	0.18	-0.27	-0.17	-0.81	-0.27	0.15		-0.74
Net Debt To E B I T D A	0.28	0.74	-0.29	-0.61	0.0	0.21	0.28	-0.67	-0.26	-0.46	0.04	0.63	0.71	0.3	0.2	0.71	-0.01	0.19	-0.45	0.72	0.65	0.74	0.72	-0.32	-0.74

Click cells to compare fundamentals

Adial Pharmaceuticals Account Relationship Matchups

Adial Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	3.33	5.32	14.31	1.78	0.65	0.68
Book Value Per Share	18.12	8.0	4.72	3.08	2.87	4.97
Free Cash Flow Yield	(0.27)	(0.36)	(0.24)	(1.91)	(2.2)	(2.09)
Operating Cash Flow Per Share	(16.08)	(15.31)	(16.07)	(10.52)	(4.78)	(5.02)
Average Payables	144.9K	419.5K	467.5K	201.9K	181.7K	232.7K
Pb Ratio	3.33	5.32	14.31	1.78	0.65	0.68
Free Cash Flow Per Share	(16.08)	(15.31)	(16.16)	(10.52)	(12.1)	(12.71)
Roic	(1.14)	(2.73)	(5.47)	(3.99)	(1.69)	(1.77)
Net Income Per Share	(21.8)	(21.79)	(26.12)	(11.98)	(4.92)	(5.16)
Payables Turnover	0.00297	8.69E-4	0.19	0.22	0.004427	0.004206
Cash Per Share	17.2	8.83	8.15	3.76	1.99	1.89
Pocfratio	(3.75)	(2.78)	(4.2)	(0.52)	(0.39)	(0.41)
Pfcf Ratio	(3.75)	(2.78)	(4.18)	(0.52)	(0.47)	(0.49)
Days Payables Outstanding	122.9K	419.8K	1.9K	1.7K	82.4K	84.6K
Income Quality	0.74	0.7	0.62	0.88	0.97	0.51
Roe	(1.2)	(2.72)	(5.54)	(3.89)	(1.71)	(1.8)
Ev To Operating Cash Flow	(2.68)	(2.2)	(3.71)	(0.18)	0.0262	0.0275
Pe Ratio	(2.76)	(1.95)	(2.58)	(0.46)	(0.38)	(0.4)
Return On Tangible Assets	(1.12)	(1.98)	(2.87)	(2.53)	(1.48)	(1.55)
Ev To Free Cash Flow	(8.2)	(2.68)	(2.2)	(3.69)	(0.18)	(0.17)
Earnings Yield	(0.36)	(0.51)	(0.39)	(2.18)	(2.64)	(2.51)
Intangibles To Total Assets	8.03E-4	0.001021	0.0949	0.12	8.26E-4	7.85E-4
Net Debt To E B I T D A	0.55	0.83	0.4	0.3	0.28	0.42
Current Ratio	14.24	3.41	2.37	2.67	4.9	4.46
Tangible Book Value Per Share	18.1	7.98	3.76	2.42	2.86	4.81
Graham Number	94.27	62.6	52.66	28.82	17.81	16.92
Shareholders Equity Per Share	18.12	8.0	4.72	3.08	2.87	4.97
Graham Net Net	18.97	15.83	5.81	2.82	1.45	1.53
Enterprise Value Over E B I T D A	(2.08)	(1.54)	(2.28)	(0.15)	0.0255	0.0268
Price Earnings Ratio	(2.76)	(1.95)	(2.58)	(0.46)	(0.38)	(0.4)
Price Book Value Ratio	3.33	5.32	14.31	1.78	0.65	0.68
Price Earnings To Growth Ratio	0.043	42.53	(0.13)	0.008483	0.006929	0.006583
Days Of Payables Outstanding	122.9K	419.8K	1.9K	1.7K	82.4K	84.6K
Price To Operating Cash Flows Ratio	(3.75)	(2.78)	(4.2)	(0.52)	(0.39)	(0.41)
Price To Free Cash Flows Ratio	(3.75)	(2.78)	(4.18)	(0.52)	(0.47)	(0.49)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:

How To Invest In Adial

Details

Is Adial Stock a good investment?

Details

What is Adial Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.94)

Return On Assets

(1.04)

Return On Equity

(3.21)

The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Adial Historical Financial Ratios

About Adial Financial Ratios Analysis

Adial Pharmaceuticals Financial Ratios Chart

Average Payables

Payables Turnover

Capex To Revenue

Adial Pharmaceuticals fundamentals Correlations

Adial Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adial Pharmaceuticals fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio

Capex To Depreciation	- 0.98	Free Cash Flow Yield
Earnings Yield	- 0.97	Capex To Depreciation
Ev To Free Cash Flow	- 0.93	Free Cash Flow Per Share
Ev To Operating Cash Flow	- 0.93	Free Cash Flow Per Share
Pfcf Ratio	- 0.92	Free Cash Flow Per Share
Pocfratio	- 0.92	Free Cash Flow Per Share